Materialise NV
NASDAQ:MTLS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Materialise NV
NASDAQ:MTLS
|
BE |
|
Gene Biotherapeutics Inc
OTC:CRXM
|
US |
Materialise NV
Materialise NV engages in the provision of additive manufacturing software and 3D printing services. The company is headquartered in Leuven (Louvain), Vlaams-Brabant. The company went IPO on 2014-06-25. The firm is a provider of additive manufacturing software and three dimensional (3D) printing services. Materialise NV incorporates 3D printing experience into a range of software solutions and 3D printing services, through which the Company seeks to form the backbone of the 3D printing industry. Its solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build 3D printing applications. The firm operates in the domestic market and worldwide, including Colombia, Brazil, Australia, Malaysia, China, Japan, Austria, Poland, Germany, and France, among others.
Materialise NV engages in the provision of additive manufacturing software and 3D printing services. The company is headquartered in Leuven (Louvain), Vlaams-Brabant. The company went IPO on 2014-06-25. The firm is a provider of additive manufacturing software and three dimensional (3D) printing services. Materialise NV incorporates 3D printing experience into a range of software solutions and 3D printing services, through which the Company seeks to form the backbone of the 3D printing industry. Its solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and design, and consumer goods, to build 3D printing applications. The firm operates in the domestic market and worldwide, including Colombia, Brazil, Australia, Malaysia, China, Japan, Austria, Poland, Germany, and France, among others.
Revenue Growth: Q4 revenue rose 6.8% year-on-year to EUR 70.2 million, driven mainly by strength in the Medical segment.
Profitability Rebound: Adjusted EBIT swung to a profit of EUR 4 million, with adjusted EBITDA margin climbing to 13.6%, reflecting improved operational efficiency.
Medical Segment Outperformance: Medical revenue hit a record, up 16% YoY in Q4, and is expected to continue double-digit growth in 2026.
Manufacturing Headwinds: Manufacturing revenue declined 2% YoY in Q4 due to weak industrial demand, especially in prototyping, and is expected to remain flat or down in 2026.
Software Transition: Software revenue was stable, with recurring revenue up 4% YoY as the segment advances its shift to a subscription model, set to complete in 2026.
Strong Cash Position: Net cash improved to EUR 17.8 million, with cash reserves at EUR 134 million, supporting future investments and potential M&A.
2026 Outlook: Revenue guidance set at EUR 273–283 million and adjusted EBIT expected to reach EUR 10–12 million.
